经导管三尖瓣环成形系统获批上市
国家药品监督管理局批准了上海汇禾医疗科技股份有限公司的经导管三尖瓣环成形系统创新产品注册申请。该系统包括三尖瓣环夹系统和输送鞘套件，用于缓解患者的三尖瓣反流和心衰临床症状，适用于65岁以上不适合外科手术的高危禁忌患者。药品监督管理部门将加强上市后监管，保护患者用械安全。
媒体报道
三尖瓣反流治疗新曙光：国产经导管系统获批上市 医药魔方
经导管三尖瓣环成形系统获批上市 医药魔方
中国首款经导管三尖瓣器械K-Clip获批上市 医谷网
#热门话题
BY Readhub
The seemingly negative pandemic effects and resource/product shortages are encouraging and allowing organizations to innovate and change.The news of cash-rich organizations getting ready for the post-Covid growth economy is a sign of more than capital spending plans. Cash provides a cushion for risk-taking and a tool for growth.
The STAR Market, as is implied by the name, is heavily geared toward smaller innovative tech companies, in particular those engaged in strategically important fields, such as biopharmaceuticals, 5G technology, semiconductors, and new energy. The STAR Market currently has 340 listed securities. The STAR Market is seen as important for China’s high-tech and emerging industries, providing a space for smaller companies to raise capital in China. This is especially significant for technology companies that may be viewed with suspicion on overseas stock exchanges.
Readhub from in